Company Encyclopedia
View More
name
Adagio Medical
ADGM.US
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc.
1.388 T
ADGM.USMarket value -Rank by Market Cap -/-

Financial Score

16/12/2025 Update
E
Health Care EquipmentIndustry
Industry Ranking168/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-210.36%E
    • Profit Margin-57771.53%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-74.77%E
    • Net Profit YoY-201.02%E
    • Total Assets YoY-70.57%E
    • Net Assets YoY-101.71%E
  • Cash ScoreD
    • Cash Flow Margin-0.17%D
    • OCF YoY-74.77%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio104.16%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Adagio Medical Holdings CEO Todd Usen Acquires Common Shares

    Todd Usen, CEO and Director of Adagio Medical Holdings Inc., has acquired common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

    Reuters·
    US
    ADGM
    +41.95%
    Reuters·
    US
    ADGM
    +41.95%

    Adagio Medical Holdings Appoints Sean Salmon to Board of Directors

    Adagio Medical Holdings Inc. has appointed Sean Salmon to its Board of Directors, joining the Audit and Compensation Committees. Salmon brings leadership experience from Medtronic, C.R. Bard, Johnson & Johnson, SurgiVision, and EuroRSCG Life. This announcement was originally published by Adagio Medical Holdings via Business Wire on December 11, 2025.

    Reuters·
    US
    ADGM
    +41.95%
    Reuters·
    US
    ADGM
    +41.95%

    Adagio Medical | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ADGM
    +41.95%
    LB filings·
    US
    ADGM
    +41.95%

    Adagio Medical | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ADGM
    +41.95%
    LB filings·
    US
    ADGM
    +41.95%

    Adagio Medical Holdings posts Q3 net loss of $10.1 million

    Adagio Medical Holdings Inc. reported a Q3 net loss of $10.1 million for the quarter ending September 30, 2025, compared to a $4.6 million loss in Q3 2024. Revenue costs decreased to $0.03 million, while R&D expenses rose to $2.8 million. SG&A expenses fell to $2.9 million. The company has $4.7 million in cash and completed a private placement of up to $50 million. Recent developments include the completion of a pivotal trial enrollment and the appointment of Deborah Kaster as CFO.

    Reuters·
    US
    ADGM
    +41.95%
    Reuters·
    US
    ADGM
    +41.95%
    © 2025 Longbridge｜Disclaimer